Martin Reck, MD, PhD, on Resectable/Borderline Resectable NSCLC: Neoadjuvant Durvalumab Plus Chemotherapy
IASLC WCLC 2026
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, reviews efficacy and safety data from the primary analysis of MDT-BRIDGE. The phase II study is investigating perioperative durvalumab plus neoadjuvant chemotherapy in patients with resectable/borderline resectable stage IIB–IIIB non–small cell lung cancer (NSCLC) and evaluating whether chemoradiotherapy followed by consolidation durvalumab is effective and tolerable in patients who become unresectable during neoadjuvant treatment (Abstract OA04.02).
Chad G. Rusthoven, MD, of the University of Colorado School of Medicine, presents results from the international phase III SWOG S1827 MAVERICK trial, which showed that brain MRI surveillance alone improved cognitive failure–free survival compared with MRI surveillance plus prophylactic cranial irradiation in patients with small cell lung cancer (SCLC). The findings support MRI surveillance alone as the standard of care for patients with SCLC (Abstract PL02.01).
Adam J. Schoenfeld, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from BNT324-01, an ongoing global phase Ib/II trial looking at pumitamig, an investigational PD-L1 × VEGF-A bispecific antibody, combined with elfetabart drozuntecan (BNT324/DB-1311), an investigational B7-H3–targeted antibody-drug conjugate, with a focus in small cell lung cancer (SCLC) (Abstract OA14.02).
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (Abstract PL03.03).
Roy S. Herbst, MD, PhD, of Dartmouth Cancer Center, discusses 8-year overall survival data from the landmark ADAURA trial, which showed the sustained long-term benefit of adjuvant therapy with osimertinib for patients with completely resected, EGFR-mutated stage IB–IIIA non–small cell lung cancer (NSCLC) (Abstract PL03.01).
Alberto A. Chiappori, MD, of Moffitt Cancer Center, discusses findings from a phase I trial looking at the safety and efficacy of LB2102, an autologous CAR-T cell therapy targeting DLL3 and armored with a dominant-negative TGF-beta receptor, in pretreated patients with small cell lung cancer (SCLC) (Abstract OA05.02).
